Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Decreased miR-452 expression in human cervical cancer and its prognostic significance
Xue Dong1, *, Zhong-Li Yang2, Jun Zhang3
1 Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 Department of Obstetrics and Gynecology, Shandong Provincial Hospital, Jinan, China
3 Department of Obstetrics and Gynecology, The Second People’s Hospital of Shenzhen, Shenzhen, China
Eur. J. Gynaecol. Oncol. 2018, 39(1), 27–31; https://doi.org/10.12892/ejgo3658.2018
Published: 10 February 2018
Objective: MicroRNA-452 (miR-452) was previously reported to be dysregulated in several types of human cancers and involved in tumor progression. However, its role in cervical cancer is still unclear. The aim of this study was to investigate the clinical significance and prognostic value of miR-452 expression in human cervical cancer. Materials and Methods: The expressions of miR-452 was detected in 137 pairs of cervical cancer specimens and adjacent non-cancerous tissues using qRT-PCR assay. Then, the association of miR-452 levels with clinicopathological features and prognosis was evaluated. Results: MiR-452 expression was significantly downregulated in cervical cancer tissues than those corresponding non-cancerous tissues (p < 0.001). Decreased miR-452 expression was linked to lymph node metastasis, vascular invasion, poor tumor differentiation, advanced FIGO Stage, and short overall survival. Multivariate Cox regression analysis confirmed that low level of miR-452 expression predicted poor prognosis of patients with cervical cancer independently. Conclusions: The present results suggest that miR-452 downregulation may be involved in cervical cancer formation and progression, and that miR-452 would serve as a novel prognostic biomarker for patients with this disease.
Real-time quantitative RT-PCR